Verve Therapeutics CEO Sekar Kathiresan's 2022 pay jumps 41% to $7.8M
Verve Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 28, 2023
Verve Therapeutics reported fiscal year 2022 executive compensation information on April 28, 2023.
In 2022, three executives at Verve Therapeutics received on average a compensation package of $4.8M, a 19% increase compared to previous year.
Average pay of disclosed executives at Verve Therapeutics
Sekar Kathiresan, Chief Executive Officer, received $7.8M in total, which increased by 41% compared to 2021. 89% of Kathiresan's compensation, or $6.9M, was in option awards. Kathiresan also received $316K in non-equity incentive plan, $571K in salary, as well as $12K in other compensation.
Andrew Bellinger, Chief Scientific Officer, received a compensation package of $3.3M, which is about the same as previous year. 79% of the compensation package, or $2.6M, was in option awards.
Andrew Ashe, Chief Operating Officer, earned $3.3M in 2022.
Related executives
You may also like
Source: SEC filing on April 28, 2023.